Spark Therapeutics to Present Updated Hemophilia B Data at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress
23. Juni 2017 02:00 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, June 23, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Participate in Multiple Conferences in June
01. Juni 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, June 01, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Completes Rolling Biologics License Application Submission to FDA for Investigational Gene Therapy Voretigene Neparvovec
18. Mai 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 18, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Reports First Quarter 2017 Financial Results and Recent Business Progress
09. Mai 2017 07:30 ET
|
Spark Therapeutics, Inc.
Work on U.S. Biologics License Application (BLA) for investigational voretigene neparvovec is complete Interim results from SPK-7001 Phase 1/2 clinical trial in choroideremia reported;...
Spark Therapeutics to Participate in Multiple Meetings in May
03. Mai 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Host Conference Call on Tuesday, May 9 at 8:30 a.m. to Discuss Q1 2017 Results
02. Mai 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, May 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
Spark Therapeutics Presents Updated Preliminary Data from Hemophilia B Phase 1/2 Trial Suggesting Consistent and Sustained Levels of Factor IX Activity at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium
06. April 2017 07:30 ET
|
Spark Therapeutics, Inc.
As of data cutoff, the annualized bleeding rate (ABR) has been reduced by 96 percent and the annualized infusion rate (AIR) reduced by 99 percent Both participants who began a tapering course of...
Spark Therapeutics to Present Updated Hemophilia B Data at the Hemostasis and Thrombosis Research Society (HTRS) 2017 Scientific Symposium
04. April 2017 16:15 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, April 04, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Participate in Multiple Conferences in March
02. März 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, March 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics and Pfizer Announce that SPK-9001, an Investigational Hemophilia B Medicine, has been Granted Access to the PRIority MEdicines (PRIME) Program by the European Medicines Agency
01. März 2017 16:15 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA and NEW YORK, March 01, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE) and Pfizer Inc. (NYSE:PFE) announced today that SPK-9001, the lead investigational candidate in the...